Cell-Penetrating Peptide Delivers Nerve Growth Factor Through the Eye to Protect the Brain
NGF combined with a cell-penetrating peptide delivered via eye drops showed enhanced neuroprotective activity, offering a non-invasive route for treating neurodegenerative diseases.
Quick Facts
What This Study Found
CPP-conjugated NGF delivered ophthalmically showed enhanced neuroprotective activity compared to NGF alone, leveraging the eye-brain connection for non-invasive brain drug delivery.
Key Numbers
L-PenetraMax significantly enhanced NGF delivery efficiency to the optic nerve through topical ophthalmic administration.
How They Did This
Combined NGF with cell-penetrating peptide. Formulated as ophthalmic delivery. Assessed ocular penetration, brain delivery, and neuroprotective activity.
Why This Research Matters
Neurodegenerative diseases like Alzheimer's and Parkinson's have no cure. Eye drops that deliver neuroprotective proteins to the brain via peptide technology could make treatment accessible and non-invasive.
The Bigger Picture
The eye-brain connection (via the optic nerve and associated pathways) is an emerging route for brain drug delivery that bypasses the blood-brain barrier. Combining this route with cell-penetrating peptides could enable eye drop delivery of proteins and peptides for brain diseases.
What This Study Doesn't Tell Us
Preclinical study. The amount of NGF reaching the brain via eye drops may be limited. Long-term safety of repeated CPP-protein eye administration needs evaluation.
Questions This Raises
- ?Could CPP-NGF eye drops slow progression of Alzheimer's or Parkinson's disease?
- ?What percentage of the NGF dose reaches the brain via ophthalmic delivery?
- ?Can other neuroprotective proteins be delivered using this CPP-eye drop approach?
Trust & Context
- Key Stat:
- Eye drops to brain CPP-conjugated NGF delivered as eye drops reaches the brain via the eye-brain connection, providing non-invasive neuroprotection
- Evidence Grade:
- Preliminary evidence: preclinical proof-of-concept for CPP-enhanced ophthalmic neuroprotective delivery.
- Study Age:
- Published in 2024. Explores a novel delivery route for brain-targeted peptide therapy.
- Original Title:
- Enhanced neuroprotective activity of ophthalmic delivered nerve growth factor conjugated with cell penetrating peptide against optic nerve injury.
- Published In:
- Journal of drug targeting, 32(1), 93-99 (2024)
- Authors:
- Zhu, Danni, Li, Yao, Zhang, Jinlong, Chen, Yi, Song, Xiaohong, Chen, Wei, Wu, Shipo, Hou, Lihua
- Database ID:
- RPEP-09690
Evidence Hierarchy
Frequently Asked Questions
Can eye drops deliver drugs to the brain?
Yes — the eye and brain are connected via the optic nerve and other pathways. This study shows that combining nerve growth factor with a cell-penetrating peptide in eye drops enhanced its delivery to the brain and improved neuroprotective activity.
What is nerve growth factor?
NGF is a protein that supports the survival and function of brain neurons. It has neuroprotective potential for conditions like Alzheimer's, but delivering it to the brain has been a major challenge — one that CPP-enhanced eye drops may solve.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09690APA
Zhu, Danni; Li, Yao; Zhang, Jinlong; Chen, Yi; Song, Xiaohong; Chen, Wei; Wu, Shipo; Hou, Lihua. (2024). Enhanced neuroprotective activity of ophthalmic delivered nerve growth factor conjugated with cell penetrating peptide against optic nerve injury.. Journal of drug targeting, 32(1), 93-99. https://doi.org/10.1080/1061186X.2023.2295220
MLA
Zhu, Danni, et al. "Enhanced neuroprotective activity of ophthalmic delivered nerve growth factor conjugated with cell penetrating peptide against optic nerve injury.." Journal of drug targeting, 2024. https://doi.org/10.1080/1061186X.2023.2295220
RethinkPeptides
RethinkPeptides Research Database. "Enhanced neuroprotective activity of ophthalmic delivered ne..." RPEP-09690. Retrieved from https://rethinkpeptides.com/research/zhu-2024-enhanced-neuroprotective-activity-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.